Chet Metcalf
Vice President, Chemistry Head of Research & Development Regeneron Pharmaceuticals
Chet Metcalf is Vice President, R&D Chemistry – VI Antibody at Regeneron, where he leads chemistry efforts supporting the discovery and development of next-generation biologics and ADCs. With more than two decades of drug discovery experience, he has overseen multidisciplinary teams spanning medicinal chemistry, structure-based design, DMPK, and platform technologies, advancing candidates from early discovery through IND. Prior to Regeneron, he held leadership roles at Mariana Oncology, Novartis, Cubist, and ARIAD, contributing to radiopharmaceutical, drug conjugate, and small-molecule innovation. Chet is a co-inventor of two FDA-approved drugs and co-author of more than 80 publications and patents.
Seminars
- Breaking down discovery and lessons learned from REGN5093 (METxMET)-M114 biparatopic ADC
- Exploring the Regeneron ProDXd platform for discovery and development of differentiated ADCs
- Assessing novelty and discovery of targeting GPCRs with Antibody Tethered Ligand (ATL) conjugates
At the end of the seminar day, don’t miss this summary panel discussion to discuss, debate and challenge your speakers and ADC peers on the cutting-edge of ADC design, exploring the most promising areas of ADC innovation, benefits against traditional therapies, and hurdles to advance novel conjugates into and through the clinic.
- Evaluating the landscape of ADC therapies one year on: Is the field pursuing the right amount of innovation to secure the next wave of ADCs beyond Topo1?
- Delving into payload mechanisms and non-traditional ADC design: What avenues of innovation are showing promise and what needs to be demonstrated?
- Assessing hurdles and opportunities to achieve differentiated ADC clinical profiles and patient impact in crowded oncology indications
- Peering into the crystal ball: Debating the future direction of the ADC field and pioneering future possibilities
